Browse the evidence

Obesity induces a state of chronic low-grade systemic inflammation originating in adipose tissue, driven by macrophage infiltration, altered adipokine secretion (increased leptin, decreased adiponectin), and metabolic stressors like free fatty acids and hypoxia.

Recognize that excess body fat, particularly visceral fat, triggers a biological inflammatory response that can worsen metabolic health. While lifestyle changes like physical activity can help reduce this inflammation, understanding the biological basis of obesity can help reduce stigma and highlight the importance of comprehensive health management beyond just weight loss.

Metformin, a widely used antidiabetic drug, activates AMPK indirectly by inhibiting mitochondrial complex I, which lowers cellular energy status and thereby activates the AMPK pathway.

Metformin, a common diabetes medication, works by slightly inhibiting your mitochondria's energy production. This small drop in energy triggers your AMPK sensor, which improves your body's ability to manage blood sugar and burn fat. It essentially tricks your body into thinking it is in a low-energy state, promoting metabolic health.

Activation of the IGF1-Akt/PKB pathway in skeletal muscle drives hypertrophy by simultaneously stimulating protein synthesis via mTOR and inhibiting protein degradation via FoxO transcription factors.

To build muscle, you must stimulate the IGF1-Akt pathway. This happens naturally through resistance training and adequate nutrition. The paper confirms that activating this pathway increases muscle size by building protein and stopping breakdown. Focus on progressive overload in training and sufficient protein intake to support this biological process.

In non-insulin-dependent diabetes mellitus (NIDDM), insulin resistance is a general characteristic affecting both glucose and free fatty acid (FFA) metabolism, involving impaired suppression of hepatic glucose production and FFA turnover.

For individuals with NIDDM, insulin resistance is not just about blood sugar; it extends to how the body handles fats. High rates of fat oxidation can worsen glucose control and liver glucose production. Managing lipid metabolism is as critical as managing glucose.

Persistent hyperglycemia accelerates endogenous AGE formation through the Maillard reaction and dicarbonyl stress, leading to RAGE activation, oxidative stress, and insulin resistance.

Maintaining blood glucose levels within target ranges is critical to preventing the formation of endogenous AGEs and subsequent tissue damage.

Obesity and metabolic syndrome significantly increase the risk of hepatocellular carcinoma (HCC), with risk escalating as BMI increases and being further amplified by the presence of type 2 diabetes.

Maintaining a healthy body weight is a critical strategy for reducing the risk of liver cancer. The risk of developing hepatocellular carcinoma increases significantly with higher BMI, and this risk is even higher if you have type 2 diabetes. Focus on metabolic health through diet and lifestyle changes to lower this risk.

Palmitic acid is essential for physiological functions including maintaining membrane fluidity, protein palmitoylation, and lung surfactant activity (DPPC), and its deficiency can impair lung function.

Palmitic acid is not just 'bad fat'; it is essential for your lungs (surfactant), cell membranes, and protein signaling. Your body makes it and needs it. The problem arises not from its presence, but from excess production due to sugar and calorie overload.

In patients with type 2 diabetes, the characteristic dyslipidemia (low HDL, small dense LDL, elevated triglycerides) is strongly associated with increased cardiovascular disease risk, driven by insulin resistance and altered VLDL metabolism.

If you have type 2 diabetes, standard cholesterol tests might not tell the whole story. You are at higher risk for heart disease due to specific changes in your blood fats (like small, dense LDL and low HDL) driven by insulin resistance. This risk exists even if your total LDL looks normal. Managing this requires addressing the underlying insulin resistance through lifestyle changes (diet, exercise) and often medication, not just focusing on total cholesterol numbers.

Obesity causes approximately 20% of all cancer cases, with specific mechanisms varying by cancer site (e.g., estrogen for breast/endometrial, insulin for colon/prostate, inflammation for others).

Maintaining a healthy weight is one of the most significant actions you can take to reduce your risk of developing many common cancers. While the biological mechanisms vary (hormones, insulin, inflammation), the common denominator is excess body fat. Weight management strategies that reduce adiposity can lower cancer risk across multiple types.

GIP signaling is selectively impaired in type 2 diabetes, reducing its insulinotropic effect, while GLP-1 signaling remains substantially preserved.

In Type 2 Diabetes, your body's natural response to GIP is blunted, which is why GLP-1 based medications are often more effective for stimulating insulin than therapies targeting GIP.

Obesity induces chronic low-grade metabolic inflammation in adipose tissue, primarily through macrophage infiltration and the secretion of pro-inflammatory cytokines like TNF-alpha and IL-6, which directly causes insulin resistance and metabolic dysfunction.

Understanding that obesity creates a biological state of chronic inflammation helps explain why weight loss is difficult and why metabolic health declines. This is not a moral failing but a physiological response where fat tissue actively signals the body to store more fat and resist insulin. Treatments targeting this inflammation (like managing cytokine levels) may be necessary alongside lifestyle changes.

Leptin resistance in obese individuals renders exogenous leptin therapy ineffective for weight loss, despite leptin's potent role in regulating energy balance and satiety.

Leptin supplements or therapies are generally ineffective for weight loss in typical obesity because the body has become resistant to the hormone. This is why simply 'adding more leptin' doesn't work. Focus should be on improving leptin sensitivity through lifestyle changes rather than seeking leptin-based treatments.

Chronically elevated plasma free fatty acid (FFA) levels cause insulin resistance in muscle and liver and impair insulin secretion in pancreatic beta-cells, a process termed lipotoxicity.

In Type 2 Diabetes, high levels of free fatty acids in the blood drive insulin resistance in muscles and the liver, and damage the pancreas's ability to make insulin. This 'lipotoxicity' is caused by fat cells failing to store fat properly, leading to fat accumulating in organs where it shouldn't be. Reducing these fatty acid levels (e.g., via medications like thiazolidinediones or lifestyle changes that improve fat storage capacity) can improve insulin sensitivity.

Adipose tissue acts as an endocrine organ, secreting hormones like leptin and adiponectin that regulate systemic metabolism, insulin sensitivity, and energy expenditure.

Understand that your fat cells send signals to your brain and other organs. Healthy fat levels help regulate hunger (leptin) and insulin sensitivity (adiponectin). Disrupting these signals through extreme dieting or obesity can lead to metabolic dysfunction.

In patients with impaired glucose tolerance, insulin resistance is caused solely by decreased insulin receptor numbers (receptor defect), resulting in a rightward shift of the dose-response curve without a reduction in maximal glucose disposal capacity.

If you have impaired glucose tolerance (pre-diabetes), your body's ability to process glucose at high insulin levels is likely intact. The primary issue is that you have fewer insulin receptors, so you need higher insulin levels to achieve the same glucose disposal as a healthy person. This suggests that lifestyle interventions improving insulin sensitivity (like exercise) can help compensate for the lower receptor count by making the existing receptors more efficient or by lowering the baseline insulin demand.

In patients with Type II diabetes and fasting hyperglycemia, insulin resistance is caused by both decreased insulin receptors AND a postreceptor defect, leading to a reduced maximal rate of glucose disposal.

For those with established Type II diabetes, simply lowering insulin levels (if possible) or increasing receptor sensitivity is not enough because the cells' internal ability to process glucose is also damaged. Treatment must address both the signaling issue (receptors) and the internal processing issue (postreceptor defects), often requiring medication that bypasses or enhances these pathways.

Insulin's ability to suppress hepatic glucose output is preserved in both impaired glucose tolerance and Type II diabetes, with no postreceptor defect detected in the liver.

Even in Type II diabetes, the liver retains the ability to stop producing glucose when insulin levels are high enough. This suggests that therapies aiming to suppress hepatic glucose production (like metformin or GLP-1 agonists) may still be effective because the liver's basic response mechanism is not broken, just less sensitive.

In postmenopausal women with a normal baseline BMI (<25.0), gaining more than 5% of body weight during follow-up is associated with an increased risk of invasive breast cancer.

Postmenopausal women with a normal weight should be vigilant about avoiding significant weight gain (more than 5% of body weight), as this increases breast cancer risk. This highlights that weight stability is important even for those who are not currently overweight.

The pathophysiological link between NAFLD and CVD is driven by systemic inflammation, endothelial dysfunction, and atherogenic dyslipidemia (specifically high ApoC3 and small dense LDL) resulting from hepatic fat accumulation and insulin resistance.

Understanding that liver fat drives heart risk through inflammation and bad cholesterol helps explain why lifestyle changes (diet/exercise) that reduce liver fat also protect the heart. It is not just about weight loss, but improving metabolic health.

Genetic mutations in the Melanocortin-4 Receptor (MC4R) are a common cause of severe childhood and adult obesity, resulting in hyperphagia and increased fat and lean mass.

If you have severe obesity starting in childhood, ask about genetic testing for MC4R mutations. This is a known genetic cause affecting up to 5% of severe cases. Understanding this can guide medical treatment, as standard weight loss advice may be less effective without addressing the specific receptor dysfunction.

Current use of oral estrogen increases the risk of venous thromboembolism in postmenopausal women, with the highest risk occurring during the first year of treatment.

If you are a postmenopausal woman considering hormone replacement therapy, be aware that taking estrogen orally increases your risk of blood clots (venous thromboembolism), especially during the first year of use. This risk is roughly 2.5 times higher than in non-users. However, using estrogen through the skin (transdermal patches/gels) does not appear to increase this clotting risk, making it a potentially safer option to discuss with your doctor.

Central nervous system leptin signaling regulates energy balance and body weight primarily through the JAK-STAT3 pathway acting on hypothalamic neurons, specifically by activating pro-opiomelanocortin (POMC) neurons and inhibiting neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons.

Your body produces leptin to signal fullness to your brain. In obesity, this signal often gets ignored (leptin resistance). Simply having high leptin doesn't fix this; the issue is how the brain processes the signal, not the amount of leptin itself.

Gestational diabetes mellitus (GDM) is the most prominent independent risk factor for the progression to type 2 diabetes in women, increasing the relative risk by approximately 8.3-fold.

If you had gestational diabetes, your risk of developing type 2 diabetes is over 8 times higher than women who did not. This risk persists for years. You need lifelong, regular glucose monitoring and lifestyle interventions, as standard postpartum care often neglects this long-term metabolic risk.

Female age is a primary determinant of reproductive performance, with a significant decline in fertility starting in the mid-to-late 20s and a steep drop after age 35, affecting both natural conception and ART success rates.

If you are a woman planning to conceive, understand that fertility begins to decline in your late 20s and drops significantly after 35. This is a biological fact, not a lifestyle choice. If you are not ready to conceive by your early 30s, consider discussing egg freezing or other preservation options with a specialist, as waiting until 40 drastically reduces the chance of live birth via ART.